|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Delaware
|
|
001-33958
|
|
20-8099512
|
(State or other jurisdiction of incorporation or organization)
|
|
(Commission
File Number) |
|
(I.R.S. Employer
Identification No.) |
|
|
|
|
|
|
|
2000 Crow Canyon Place, Suite 380, San Ramon, CA 94583
|
|
|
|
|
(Address of Principal Executive Offices) (Zip Code)
|
|
|
|
|
|
|
|
Registrant’s telephone number, including area code: (855) 855-4253
|
||||
|
|
|
|
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
Item 3.02
|
Unregistered Sales of Equity Securities.
|
•
|
With respect to interest accruing on the outstanding principal amount under the Debenture for the period prior to November 10, 2016, the Company was permitted to satisfy such interest payments in kind by adding such amount to the outstanding principal.
|
•
|
The Purchaser can from time to time during the term of the Debenture require the Company to prepay in cash all or a portion of the outstanding principal plus accrued and unpaid interest (the “Outstanding Amount”) on written notice to the Company, provided, that such prepayment amount shall not exceed the lesser of $18,500,000 and the Outstanding Amount. If the holder elects such prepayment of the Debenture, then the number of shares subject to the warrants issued to the holder will be reduced in proportion to the percentage of principal and accrued interest required to be prepaid by the Company. In addition, the Company shall have the right to prepay in cash all (but not less than all) of the Outstanding Amount (1) at any time after November 10, 2017, or (2) upon a “change of control” (as such term is used un the Debenture), in each case with a 10% premium on the Outstanding Amount.
|
•
|
The Purchaser shall continue to have the right, which commenced on November 10, 2016, to require the Company to redeem the Outstanding Amount, except that the maximum monthly amount of such redemptions was increased from $1,100,000 to $1,500,000; provided, that if the trading price of Common Stock is at least $8.00 per share (as may be further adjusted appropriately for stock splits, combinations or similar events) during such calendar month, then such monthly maximum redemption amount may be increased to $2,200,000 at the Purchaser’s election and if the Company has already elected to satisfy such redemptions in shares of Common Stock. In addition, notwithstanding the foregoing limitations on the monthly redemption amount, the Purchaser may elect up to three times in any 12-month period to increase the monthly maximum to $2,500,000.
|
•
|
Among the various conditions that must be satisfied (or waived) in order for the Company to be able to elect to satisfy the monthly redemption amounts in shares of Common Stock, the Original Minimum Price Condition of $15.00 was decreased to a volume-weighted average price of $4.00 per share (the “Amended Minimum Price Condition”).
|
•
|
Following November 10, 2016, the Purchaser may elect to convert any portion of the Outstanding Amount into shares of Common Stock at a fixed price of $12.00 per share (as adjusted appropriately for stock splits, combinations or similar events).
|
•
|
Under the Initial Debenture, the Company was required to maintain a minimum of $24,000,000 of unencumbered cash in a restricted account as security for its obligations under the Initial Debenture. Such minimum amount has been reduced to the lesser of $18,500,000 or the Outstanding Amount.
|
Item 9.01
|
Financial Statements and Exhibits
|
10.1
|
Amendment Agreement dated May 1, 2017 between Galena Biopharma, Inc. and JGB (Cayman) Newton Ltd.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
GALENA BIOPHARMA, INC.
|
||||
|
|
|
|
|
||||
Date:
|
|
May 2, 2017
|
|
|
|
By:
|
|
/s/ Thomas J. Knapp
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Thomas J. Knapp
|
|
|
|
|
|
|
|
|
Interim General Counsel and Corporate Secretary
|
|
Galena Biopharma, Inc., as Company
|
|
By
/s/Stephen F. Ghiglieri
Name: Stephen F. Ghiglieri
Title: Interim Chief Executive Officer
Apthera, Inc., as Guarantor
By
/s/Stephen F. Ghiglieri
Name: Stephen F. Ghiglieri
Title: Interim Chief Executive Officer
Mills Pharmaceuticals, LLC, as Guarantor
By
/s/Stephen F. Ghiglieri
Name: Stephen F. Ghiglieri
Title: Interim Chief Executive Officer
|
|
JGB (Cayman) Newton Ltd., as Holder
|
|
By
/s/Brett Cohen
Name: Brett Cohen
Title: President
JGB Collateral LLC, as Agent
By
/s/Brett Cohen
Name: Brett Cohen
Title: President
|